European Parliament Interest Group launches white paper on boosting the use of rapid diagnostic technologies to tackle antimicrobial resistance
On May 31st The European Parliament Interest Group on Innovation in Health and Social Care called on the European Commission to boost funding and innovation to foster the uptake of rapid diagnostic technologies in the upcoming Action Plan.
- Cristian-Silviu Busoi (EPP, Romania)
- Marian Harkin (ALDE, Ireland)
- Karin Kadenbach (S&D, Austria)
- Kay Swinburne (ECR, United Kingdom)
Abuse of antibiotics is one of the most significant drivers for multidrug-resistant bacteria. Antibiotic consumption widely varies between EU/EEA countries. In the countries with the highest consumption, people consume 3.4 times more antibiotics compared to countries with the lowest consumption.
Innovative diagnostic technologies can contribute – as part of a broader and coordinated plan – to reduce antibiotic misuse. To create a situation in which antimicrobials are prescribed based on diagnosis, in conjunction with presentation and clinical experience, the White Paper calls upon the European Commission and European Centre for Disease Prevention and Control to:
- Promote the use of rapid diagnostic technologies in screening programme guidelines for drug resistant bacteria.
- Set up a European monitoring programme capable of tracking implementation and the use of rapid diagnostic tools and outcomes in European healthcare systems.
- Champion in their awareness-raising campaigns the critical role of the use of rapid diagnostic technologies in tackling antimicrobial resistance.
- Develop public health messages to enable a change in patient behaviour towards antibiotic misuse.
- Encourage the uptake of rapid diagnostics in preventing antimicrobial resistance by creating a rapid diagnostic market stimulus in Europe. Funding targeted research for innovative rapid technologies.
- Promote alternative reimbursement systems to facilitate the uptake of innovative technologies in national healthcare systems.
- Implement “one horizon scanning” tools to facilitate the development of clinical evidence for rapid diagnostics.
- Take the lead in advocating evidence-based best practice models for rapid diagnostic tools.
The companies, websites, products and services, and brands referenced and linked to/from this website are not sponsored or endorsed by, or otherwise affiliated with, Alere or TestTargetTreat.com. The third-party products and services referenced and linked to/ from this website are included for informational purposes only, and have not been tested or approved by Alere or TestTargetTreat.com. Neither Alere nor TestTargetTreat.com makes any representations or warranties regarding third-party products or services, and shall not be liable for any claims arising from those products or services or your use thereof.